News for Nevro Corp. (NVRO)

On April 3, 2025, Globus Medical Inc (GMED), a prominent musculoskeletal technology company, announced the successful completion of its acquisition of Nevro Cor

AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announce...

NEW YORK, March 23, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations

Arcellx Inc (ACLX), a biotechnology firm focused on developing innovative immunotherapies for cancer and other incurable diseases, announced the appointment of

On March 3, 2025, Beryl Capital Management LLC (Trades, Portfolio) executed a noteworthy transaction by acquiring 2,444,319 shares of Nevro Corp (NVRO) at a pri

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer a

NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market.

NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level.

Nevro (NVRO) delivered earnings and revenue surprises of 18.99% and 1.49%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

PR NewswireREDWOOD CITY, Calif., March 4, 2025 REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device compan

Quarterly Revenue: $105.5 million, surpassing the estimated $102.54 million but marking a 9.1% decline year-over-year.Quarterly EPS: Reported at -$1.41, signif

Nevro Corp (NVRO) is set to release its Q4 2024 earnings on Mar 4, 2025. The consensus estimate for Q4 2024 revenue is $102.54 million, and the earnings are exp

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations o

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations o

PR NewswireNEW YORK, Feb. 25, 2025 NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

PR NewswireMILWAUKEE, Feb. 24, 2025 MILWAUKEE, Feb. 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Nevro (NYSE: NVRO) for possible breaches of fi

**media[546164]**

Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read why I'm neutral on GMED stock.

On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio) executed a strategic stock transaction involving Nevro Corp (NVRO). The firm added 8,000 shares